shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)

    PAR-24-238

    National Institutes of Health

    Opening date 17 Jun 2024, 12:00AM

    Closing date 2 Jun 2027, 12:00AM

    Funding Opportunity Number: PAR-24-238

    Opportunity Category: Discretionary

    CFDA Number(s): 93.121 -- Oral Diseases and Disorders Research,93.213 -- Research and Training in Complementary and Integrative Health,93.313 -- NIH Office of Research on Women's Health,93.393 -- Cancer Cause and Prevention Research,93.866 -- Aging Research

    Cost Sharing or Matching Requirement: No

    Posted Date: Jun 17, 2024 12:00:00 AM EDT

    Closing Date: Jun 02, 2027 12:00:00 AM EDT

    Award Ceiling: none

    Award Floor: none

    Eligible Applicants: Private institutions of higher education,Others (see text field entitled "Additional Information on Eligibility" for clarification),Public housing authorities/Indian housing authorities,State governments,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Small businesses,City or township governments,Public and State controlled institutions of higher education,Native American tribal organizations (other than Federally recognized tribal governments),For profit organizations other than small businesses,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,County governments,Special district governments,Independent school districts,Native American tribal governments (Federally recognized)

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

    Agency Name: National Institutes of Health

    Description: The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award mechanism, R61/R33 Phased Innovation Award. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. The first phase, funded by the R61, will providing for up to 2 years to identify unique host biological patterns (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with heterogeneity of probiotic clinical effects using observational or secondary data analysis studies. The second phase, funded under the R33, will support studies to assess the ability of the unique patterns determined in the R61 phase to detect the improvement of probiotic responsiveness in rigorously designed mechanistic studies in relevant animal models or in human subjects. The combined R61/R33 should not exceed 5 years. Transition from the R61 to the R33 phase of the award will be administratively reviewed and will be determined based on successful completion of Transition Milestones that need to be clearly specified in the R61 phase application. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion (R33) NOFO, PAR-AT-24-XXX (TEMP-25413).

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept